Screener
CG Oncology CGON Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -4,056.2%+24,490pp | -4,239%+16,063pp | -4,722.1%+5,345pp | -8,285.3%+5,746pp | -28,546.1%-15,974pp | |
| Net margin | -3,602.7%+19,643pp | -3,682.6%+12,263pp | -3,985%+3,744pp | -6,968%+3,675pp | -23,245.2%-13,375pp | |
| Returns | ||||||
| Return on equity | -26.4%-5.5pp | -20.8%-4.2pp | -21.7%— | -24.7%— | -21%— | |
| Return on invested capital | -30.2%-3.6pp | -24.9%-1.6pp | -31.7%— | -31.5%— | -26.6%— | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×— | 0×— | |
| Liquidity | ||||||
| Current ratio | 22.2×+0.1× | 31.3×+0.3× | 24.6×-10.7× | 22.8×-12.5× | 22.2×-25.4× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $11.67+32.7% | $12.92+39.6% | $9.74-17.0% | $8.96+12.1% | $8.79+6.1% | |
| Valuation | ||||||
| Market capitalization | $6.6B+242% | $5.71B+206% | $3.35B+53.4% | $3.07B+22.1% | $1.97B-6.5% | |
| Price / sales | 1,060×-2,439× | 1,126.9×-1,693× | 829×-1,088× | 1,412.7×-2,264× | 3,569.2×+332× | |
| Price / book | 6.4×+3.5× | 5.2×+2.6× | 4.5×+1.5× | 4.5×-0.2× | 2.9×-0.9× |
FAQ
- Where do CG Oncology's ratios come from?
- Every ratio is computed from CG Oncology's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
